Differences in outcome for consecutive patients with diffuse large B-cell lymphoma before and after the advent of rituximab: a single-center experience

References

• Flowers CR, Sinha R, Vose JM. Improving outcomes for patients with diffuse large B-cell lymphoma. CA Cancer J Clin. 2010;60:393–408.
   PubMed Web of Science ®Google Scholar
• Izumo T, Maseki N, Mori S, Tsuchiya E. Practical utility of the revised European-American classification of lymphoid neoplasms for Japanese non-Hodgkin's lymphomas. Jpn J Cancer Res. 2000;91:351–60.
   PubMedGoogle Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–42.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121–7.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379–91.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105–16.
   PubMed Web of Science ®Google Scholar
• Elting LS, Cooksley C, Bekele BN, Frumovitz M, Avritscher EB, Sun C, et al. Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants. Cancer 2006;106:2452–8.
   PubMedGoogle Scholar
• Ghesquieres H, Ferlay C, Sebban C, Chassagne C, Carausu L, Gargi T, et al. Combination of rituximab with chemotherapy in diffuse large B-cell lymphoma. Evaluation in daily practice before and after approval of rituximab in this indication. Hematol Oncol. 2008;26:139–47.
   PubMed Web of Science ®Google Scholar
• Nagai H, Yano T, Watanabe T, Uike N, Okamura S, Hanada S, et al. Remission induction therapy containing rituximab markedly improved the outcome of untreated mature B cell lymphoma. Br J Haematol. 2008;143:672–80.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23:5027–33.
   PubMed Web of Science ®Google Scholar
• Park YH, Lee JJ, Ryu MH, Kim SY, Kim DH, Do YR, et al. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients. Ann Hematol. 2006;85:257–62.
   PubMed Web of Science ®Google Scholar
• Nishimori H, Matsuo K, Maeda Y, Nawa Y, Sunami K, Togitani K, et al. The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma: a propensity score matching analysis. Int J Hematol. 2009;89:326–31.
   PubMed Web of Science ®Google Scholar
• Seki R, Ohshima K, Nagafuji K, Fujisaki T, Uike N, Kawano F, et al. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group. Int J Hematol. 2010;91:258–66.
   PubMed Web of Science ®Google Scholar
• Bari A, Marcheselli L, Sacchi S, Marcheselli R, Pozzi S, Ferri P, et al. Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. Ann Oncol. 2010;21:1486–91.
   PubMed Web of Science ®Google Scholar
• Gatter KC, Warnke RA. Diffuse large B-cell lymphoma. In: , Jaffe ES, Harris NL, Stein H, Vardiman JW (eds.) World Health Organization Classification of Tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. 171–4.
   Google Scholar
• A predictive model for aggressive non-Hodgkin's lymphoma. The international non-Hodgkin's lymphoma prognostic factors project. N Engl J Med. 1993;329:987–94.
   PubMed Web of Science ®Google Scholar
• Niitsu N, Iijima K, Chizuka A. A high serum-soluble interleukin-2 receptor level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma. Eur J Haematol. 2001;66:24–30.
   PubMed Web of Science ®Google Scholar
• Goto N, Tsurumi H, Goto H, Shimomura YI, Kasahara S, Hara T, et al. Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens. Ann Hematol. 2012;91:705–14.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.
   PubMed Web of Science ®Google Scholar
• McKelvey EM, Gottlieb JA, Wilson HE, Haut A, Talley RW, Stephens R, et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976;38:1484–93.
   PubMed Web of Science ®Google Scholar
• Niitsu N, Okamoto M, Aoki S, Okumura H, Yoshino T, Miura I, et al. Multicenter phase II study of the CyclOBEAP (CHOP-like+etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphoma. Ann Hematol. 2006;85:374–80.
   PubMed Web of Science ®Google Scholar
• LaCasce AS, Kho ME, Friedberg JW, Niland JC, Abel GA, Rodriguez MA, et al. Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network. J Clin Oncol. 2008;26:5107–12.
   PubMed Web of Science ®Google Scholar
• Proctor IE, McNamara C, Rodriguez-Justo M, Isaacson PG, Ramsay A. Importance of expert central review in the diagnosis of lymphoid malignancies in a regional cancer network. J Clin Oncol. 2011;29:1431–5.
   PubMed Web of Science ®Google Scholar
• Matasar MJ, Shi W, Silberstien J, Lin O, Busam KJ, Teruya-Feldstein J, et al. Expert second-opinion pathology review of lymphoma in the era of the World Health Organization classification. Ann Oncol. 2012;23:159–66.
   PubMed Web of Science ®Google Scholar